期刊文献+

CA242测定对恶性肿瘤的诊断价值 被引量:7

Application of CA242 IRMA in Clinical Detection
下载PDF
导出
摘要 为研究肿瘤标志物 C A242 免疫放射分析的临床应用价值,应用125 I标记糖类抗原 C242的单克隆抗体 C A242 ,固相珠用单克隆抗体 C241 包被,建立夹心的免疫放射分析( I R M A) 。结果表明,100 名正常人和53 例良性疾病患者,其 C A242 分别为567 ±581 U/ m L 和680 ±413 U/m L。如果以17 U/m L 为阳性界值测定167 例恶性肿瘤患者,其阳性率为683 % ;其中胰腺癌、结- 直肠癌、胃癌和肺癌分别有800 % 、597 % 、700 % 和600 % 的阳性率,而正常人的假阳性率为40 % 。还对 C A242 的两种测定方法( I R M A 和 E I A) 做了相关性研究,相关系数( r) 为096 。同时还应用 R O C 曲线论证了 C A242 的临床应用和价值。结论是: C A242 在恶性肿瘤诊断方面有较高的灵敏度和特异性,是一种理想的肿瘤标志物。 The object is to research the application value of the tumor marker CA242 immunoradiometric assay(IRMA)in the clinical detection.Using Mab C241 against glycoprotein antigen CA242 as the capturing antibody and Mab C242 as the labeled antibody, we have developed a“sandwich”IRMA. In Clinical detection,of all the 100 healthy,53 benign disease and 167 malignant disease serum samples,the mean concentrations of the CA 242 are 5 67±5 81U/mL,6.80±4.13U/mL and 144 69±247 04U/mL,respectively. The mean concentration of the malignant diseases is much higher than that of the healthy samples and benign disease samples.If 17U/mL is used as the cut-off value,the positive rates of the pancreatic cancer and colorectal cancer are 80.0% and 59.7%,respectively. While the false positive rate in healthy samples is 4%.In this report we ont only have made an experiment on the relativity of IRMA and EIA ( r is 0.96),but also have discussed the value of ROC curve assay in the application of CA242 IRMA in clinical cancer detection.. CA242 has higher sensitivity and specificity in the diagnosis of the malignant disease.It is an ideal tumor marker.
出处 《标记免疫分析与临床》 CAS 1999年第3期172-175,共4页 Labeled Immunoassays and Clinical Medicine
关键词 放射免疫 单克隆抗体 恶性肿瘤 CA242 Immunoradiometric assay Monoclonal antibody\ \ Pancreatic cancer detection Tumor markerrative effects of nitroglycerin combined with astragalus injection on cardiac functional insufficiency (CFI).Methods:70 cases with CFI were randomly d
  • 相关文献

同被引文献38

  • 1刘军,杨好治.胱抑素C的临床意义与测定应用[J].医学检验与临床,2008,20(2):78-79. 被引量:17
  • 2韩立军,陈智周,范振符,徐立根.CA-125免疫放射分析的稳定性研究[J].标记免疫分析与临床,1995,2(2):96-97. 被引量:1
  • 3夏吉荣,黄天禄,马志如,刘忠.血清CA_(242)测定的临床应用评价[J].中国肿瘤临床,1997,24(1):40-42. 被引量:33
  • 4赵庆荣.糖链抗原CA19-9 RIA诊断消化道癌临床意义[J].中华核医学杂志,1987,7(2):75-75.
  • 5陈智周 范振符 等.肿瘤标志物CA-50和CA-242免疫放射分析在肿瘤诊断中的应用[J].标记免疫分析与临床,1992,1(1):18-18.
  • 6吴跃平.C_(A242)──一种新的胰腺癌标志物检测的研究进展[J].国外医学(临床生物化学与检验学分册),1997,18(4):169-171. 被引量:3
  • 7Hanglund C,Ludin J,Kuusela P,et al.CA242,a newtumor marker for pancreatic cancer.a comparison with CA19-9,CA50 and CEA[J].Br J Camcer,1994,70:487~492.
  • 8武建国.医学实验诊断学进展[M](第一版)[M].南京:东南大学出版社,2000.95.
  • 9蒋国梁,杜祥.肿瘤学[M].上海:复旦大学出版社,2005:101-108.
  • 10Naylor HM,Newcomer ME. The structure of human reti nol-binding protein(RBP) with its carrier protein transt- hyretin reveals an interaction with the carboxy terminus of RBP[J]. Biochemistry, 1999,38(9) : 2647-2653.

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部